Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05870748
Title REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Sutro Biopharma, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN | AUS


No variant requirements are available.